Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Introduction to R01:11

Introduction to R

5.0K
R is a powerful software environment for statistical computing and graphics. Originating as an implementation of the S language, developed at Bell Laboratories, R has evolved into a robust, open-source statistical software favored by statisticians and data scientists worldwide. Its comprehensive suite includes data manipulation, calculation, and graphical display capabilities, making it versatile for data analysis and visualization. Its programming language is at the core of R's...
5.0K
Introduction to force01:25

Introduction to force

1.2K
Consider water flowing from a nozzle to a turbine vane. As the water hits the turbine vane, it exerts a force that causes it to move along the flow of direction. Force is an impact that changes an object's motion, shape, or orientation. Forces can be caused by physical contact, such as a push or pull, or through non-contact interactions, such as magnetic or gravitational forces. Force is a vector quantity with both magnitude and direction, and is measured in newtons (N) in the SI unit...
1.2K
Introduction to Urinary System01:13

Introduction to Urinary System

9.2K
The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
9.2K
Tonsillitis I: Introduction01:30

Tonsillitis I: Introduction

2.2K
Tonsillitis is inflammation of the tonsils, which are two lymphoid tissue masses at the back of the throat. This condition can cause discomfort and irritation in the throat.
Etiology
Three primary contributing factors have been identified.
2.2K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

908
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
908
Appendicitis-I: Introduction01:22

Appendicitis-I: Introduction

2.5K
The appendix, a small, narrow, blind tube extending from the inferior part of the cecum, is widely regarded as a vestigial organ, having lost much of its original function through evolution. Despite its diminished role, the appendix can become inflamed, a condition known as appendicitis.
Etiology: Appendicitis can arise from various causes, primarily rooted in the obstruction of the appendix lumen. Factors contributing to this obstruction include fecal accumulation, lymphoid hyperplasia and, in...
2.5K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament Analyses.

Muscle & nerve·2026
Same author

Study 19 (MCI186-19) Post Hoc Analyses.

Muscle & nerve·2026
Same author

Safety of Intravenous Edaravone in Clinical Practice.

Muscle & nerve·2026
Same author

Generalizability of Edaravone Efficacy.

Muscle & nerve·2026
Same author

Current and Ongoing Clinical Studies.

Muscle & nerve·2026
Same author

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Muscle & nerve·2025
Same journal

The Use of the Four Square Step Test and the 10-m Walk/Run Test to Determine Fall Risk in Children With Duchenne Muscular Dystrophy.

Muscle & nerve·2026
Same journal

Administration of Schwann Cell-Like Cells Differentiated From Tonsil-Derived Mesenchymal Stem Cells Promotes Peripheral Nerve Regeneration by Inducing Macrophage Polarization in a Chronic Constriction Injury Model.

Muscle & nerve·2026
Same journal

Muscle Ultrasound Is a Sensitive Outcome Measure in ALS.

Muscle & nerve·2026
Same journal

The Impact of Sponsored Genetic Testing in 170 Consecutive Consenting Patients With Amyotrophic Lateral Sclerosis: A Single-Site Retrospective Review.

Muscle & nerve·2026
Same journal

Determinants of the Maximal Nerve Cross-Sectional Area and Its Role in the Separation of Entrapment and Compression Ulnar Neuropathies at the Elbow.

Muscle & nerve·2026
Same journal

Myasthenia Gravis and Thymoma.

Muscle & nerve·2026
Ver todos los artículos relacionados
  1. Home
  3. Introducción Al Suplemento
  1. Home
  3. Introducción Al Suplemento

Video Experimental Relacionado

Dietary Supplementation of Polyunsaturated Fatty Acids in Caenorhabditis elegans
09:38

Dietary Supplementation of Polyunsaturated Fatty Acids in Caenorhabditis elegans

Published on: November 29, 2013

17.6K

Introducción al Suplemento

Kelly G Gwathmey1, Stephen Apple2

  • 1Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA.

Muscle & nerve
|February 7, 2026

Ver abstracta en PubMed

Resumen
Este resumen es generado por máquina.

La edaravona, un tratamiento para la esclerosis lateral amiotrófica (ELA), ofrece una nueva formulación de suspensión oral. Esto amplía las opciones de tratamiento para los pacientes con ELA, basándose en los beneficios establecidos de su forma intravenosa.

Palabras clave:
Estudio 19esclerosis lateral amiotróficaedaravonaeficaciaseguridad

Más Videos Relacionados

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.9K
Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
07:33

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs

Published on: July 6, 2015

12.0K

Videos de Experimentos Relacionados

Dietary Supplementation of Polyunsaturated Fatty Acids in Caenorhabditis elegans
09:38

Dietary Supplementation of Polyunsaturated Fatty Acids in Caenorhabditis elegans

Published on: November 29, 2013

17.6K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.9K
Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs
07:33

Therapeutic Effectiveness of a Dietary Supplement for Management of Halitosis in Dogs

Published on: July 6, 2015

12.0K

Área de la Ciencia:

  • Neurología
  • Farmacología
  • Investigación Clínica

Sus antecedentes:

  • La esclerosis lateral amiotrófica (ELA) es una enfermedad neuromuscular progresiva con diversas presentaciones de pacientes.
  • Los tratamientos actuales aprobados por la FDA para la ELA incluyen riluzol, edaravona (IV y oral) y tofersen.
  • La eficacia de la edaravona se demostró inicialmente en pacientes japoneses (Estudio 19), lo que llevó a la aprobación de la formulación intravenosa.

Objetivo del estudio:

  • Presentar datos que amplíen la comprensión del uso de edaravona en poblaciones más amplias de ELA.
  • Investigar la seguridad, la generalización de la eficacia, los resultados clínicos y la economía de la salud de la edaravona.
  • Informar a los médicos, investigadores y partes interesadas sobre la evidencia en evolución de la edaravona en el manejo de la ELA.

Principales métodos:

  • Revisión de datos de ensayos clínicos, análisis post hoc y estudios clínicos.
  • Enfoque en la seguridad en la práctica clínica y la generalización de la eficacia.
  • Inclusión de investigación en economía de la salud y resultados.

Principales resultados:

  • La suspensión oral de edaravona demostró buena tolerabilidad con un perfil de seguridad consistente con la edaravona intravenosa.
  • El suplemento presenta datos que amplían la base de evidencia para la edaravona en la ELA.
  • Los hallazgos cubren la seguridad, eficacia, resultados clínicos y economía de la salud.

Conclusiones:

  • La edaravona, en sus formas intravenosa y oral, es una opción terapéutica importante para la ELA.
  • La investigación y el análisis de datos continúan refinando la comprensión del papel de la edaravona en la ELA.
  • Los datos presentados respaldan la toma de decisiones informadas para el manejo de pacientes con ELA.